Urine Drugs of Abuse
[Urine Drugs of Abuse ]
EPTIS Ringversuch Nr. 187906 | Letze Änderung 2025-03-17 | URL: https://www.eptis.bam.de/pts187906 https://www.eptis.bam.de/pts187906
| Name des Anbieters | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Name des Anbieters | Weqas Weqas | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Ansässig in | United Kingdom | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Sprache(n) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anmerkungen | The initial analysis is a screening test for commonly abused drug groups, e.g opiates, benzodiazepines, barbiturates, cannabinoids, amphetamines and cocaine, drugs used in the treatment of opiate addiction (methadone and buprenorphine) and novel psychoactive substances. Initial screens are based on immunoassays (laboratory and POCT) with a further confirmatory analysis in a laboratory using GC-MS. The use of Gravimetric ‘weighed in’ values as a performance target in EQA data provides a stable, independent target that is not influenced by the overall or method mean. The linear panel of samples are distributed on a number of occasions facilitating the assessment of linearity, within and between batch precision and traceability, providing laboratories with ongoing evidence for their compliance to ISO 15189. Eighteen samples are distributed annually. Key Features: - Samples include different panels of drug / metabolites. Linear samples cover analytical and clinically relevant ranges including at or near lower limit of detection for qualitative methods. - Suitable for qualitative and quantitative results. - Suitable for both laboratory and POCT devices. - Traceable, “gravimetric” concentration of metabolite and 1° drug. - Programme assesses both laboratory and method performance, including, linearity (recovery to gravimetric), specificity, bias, within and between batch imprecision. For more information: https://www.weqas.com/participantzone/subscription-charges/ or https://www.weqas.com/services/eqa/urine-drugs-of-abuse/ or contact@weqas.com | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Klassifizierung | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Produktgruppen |
Health care / medical devices
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Prüfgebiete |
Medical analysis
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Technische Einzelheiten | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ringversuchsziele | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Zielgruppe des Ringversuchs | Urine testing for both prescribed and illicit drugs is increasingly used in both Laboratory and Point of Care settings. | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS based on ISO/IEC 17043. | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Weitere Ziele | validation of testing methods | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Teilnehmerzahl | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 |
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Kosten | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Regelmässig durchgeführt | Ja (Frequency: Bimonthly. Samples: 3 x 3.0mL) | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Der Ringversuch wird durchgeführt seit | 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Kontaktdaten des Anbieters | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anbieter | Kontaktperson | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.